Related references
Note: Only part of the references are listed.In vivo Pharmacokinetic Drug-Drug Interaction Studies Between Fedratinib and Antifungal Agents Based on a Newly Developed and Validated UPLC/MS-MS Method
Congrong Tang et al.
FRONTIERS IN PHARMACOLOGY (2021)
UPLC-MS/MS method for the quantification of ertugliflozin and sitagliptin in rat plasma
Xiangjun Qiu et al.
ANALYTICAL BIOCHEMISTRY (2019)
UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma
Ren-ai Xu et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2019)
Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis
Hang Zhao et al.
ONCOTARGETS AND THERAPY (2019)
A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors
Janice M. Mehnert et al.
INVESTIGATIONAL NEW DRUGS (2018)
In vitro anti-leukemia activity of dual PI3K/mTOR inhibitor Voxtalisib on HL60 and K562 cells, as well as their multidrug resistance counterparts HL60/ADR and K562/A02 cells
Lei Zhang et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Inhibitory effect of celecoxib on agomelatine metabolism in vitro and in vivo
Jiayang He et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial
Jennifer R. Brown et al.
LANCET HAEMATOLOGY (2018)
The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells
R. Thijssen et al.
LEUKEMIA (2016)
Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 ( XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors
Pasi A. Jaenne et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
Gautam Prasad et al.
NEURO-ONCOLOGY (2011)
Status of PI3K inhibition and biomarker development in cancer therapeutics
B. Markman et al.
ANNALS OF ONCOLOGY (2010)
Share Paper
